A key focus in discussions around the safety of nicotine pouches relates to child-resistant packaging and this is understandable. The U.S. Food and Drug Administration (FDA) has cited rising reports of accidental exposures in young children and highlighted that nicotine can be harmful in very small amounts. In response, FDA has urged manufacturers to adopt child-resistant packaging.
However, this should not obscure a more fundamental issue: product safety. A key element of product safety is the toxicological suitability of its ingredients, and a FEMA-GRAS ingredient is only proven or expected to be safe at the levels intended for use in food products.
Preferential treatment?
Regulatory review recently has appeared to focus on larger multinational tobacco manufacturers. This is sometimes perceived as preferential treatment, but a more realistic interpretation is that these companies tend to demonstrate a higher degree of procedural and scientific maturity. Established organisations are more likely to operate under robust quality systems, apply Good Manufacturing Practice (GMP), and invest significantly in ingredient selection, supplier qualification, and toxicological due diligence, a reality FDA appear to acknowledge.
In short, they are not necessarily being prioritised because of who they are, but because they are demonstrably “doing the job properly”.
This approach is also shaped by history. The tobacco industry has spent decades defending litigation associated with combustible cigarettes. That experience has fundamentally altered how large manufacturers approach newer nicotine products. Unlike cigarettes, whose risks can never be fully mitigated regardless of testing, modern nicotine products such as pouches and vapes present an opportunity to design safety into the product from the outset and remove the risk of litigation later.
Nicotine pouches as composite products
Nicotine pouches are not defined by nicotine alone. Public health authorities describe them as products that deliver nicotine alongside flavourings and other substances, via a pouch substrate, within a packaging system. From a toxicological perspective, they are composite products, where multiple materials contribute to the overall safety profile. This profile addresses the carcinogenic and genotoxic risk, as expected, but also evaluates the reproductive and sensitisation concerns which may be exacerbated by oral and mucosal administration, and provide a different risk paradigm to combustible or electronic cigarettes. To enable product differentiation, many ingredients are novel or derived from natural sources for which toxicological data are limited and which may contain small quantities of undesirable constituents. It is therefore important that these ingredients are evaluated by competent toxicologists to determine their individual and combined risks at expected levels of consumption.
These components of flavour systems, as well as pouch and packaging materials, often receive far less attention than child-resistant packaging in public discourse, despite being integral to product safety.
Regulatory scrutiny is becoming more sophisticated
In U.S. premarket tobacco product applications (PMTAs), there are currently no product specific regulations for nicotine pouches, so the toxicology focuses on nicotine delivery, harmful and potentially harmful constituents (HPHCs), and leachables from pouch materials and packaging. However, it is evident that these considerations may be of limited relevance for an oral product. The recent marketing granted orders (MGOs) awarded to the multinational tobacco companies and the limited applicability of regulatory guidance, has contributed to the accelerated number of ‘empty’ PMTA submissions which both feed the illicit market and slow down the review process. In response, FDA is now using artificial intelligence (AI) tools to screen submissions, identify inconsistencies, and flag “empty” or superficial dossiers that lack meaningful scientific substance, resulting in a ‘refusal to file’.
This shift from regulators places pressure on manufacturers to ensure their submission at least contains sufficient detail and substance to pass AI-based screening, and to determine the appropriate timing and depth of toxicological evaluation of individual components that should be included.
Why early toxicological evaluation matters
Many of the most consequential safety decisions should be made long before a product is submitted for regulatory review. Responsible ingredient selection, supplier quality controls and packaging design largely determine the toxicological risk profile of the final product, helping to avoid high costs and delays later if particular ingredient(s) require substitution or reduction.
Complementing, not replacing, packaging controls
From both a regulatory and legal perspective, confidence is not built merely on the presence of data, but on clear evidence that risks have been identified, considered and managed systematically. Products developed with early toxicological input are less likely to face late-stage regulatory challenges, reformulation requests, or future litigation.
Child-resistant packaging is an important and positive development. But it should not become a proxy for comprehensive safety assessment. Getting it right first time means recognising that toxicological suitability extends beyond child access and indeed nicotine itself, and that early, proportionate evaluation of all product components is essential to the long-term credibility